

Publications

Li H^{*}, Zhang L^{*}, Li J^{*}, Wu Q^{*}, Qian L, He J, Ni Y, Kovatcheva-Datchary P, Yuan R, Liu S, Shen L, Zhang M, Sheng B, Li P, Kang K, Wu L, Fang Q, Long X, Liu X, Wang X, Li Y, Ye Y, Ye J, Bao Y, Zhao Y, Xu G, Panagiotou G[#], Xu A[#], and Jia W[#] (2024) Resistant starch intake facilitates weight loss in humans by reshaping the gut microbiota. *Nat Metab* 6(3), 578-597.

Chen J^{*}, Leal Siliceo S^{*}, Ni Y, Nielsen HB, Xu A, Panagiotou G (2023) Identification of robust and generalizable biomarkers for microbiome-based stratification in lifestyle interventions. *Microbiome* 11(1), 178.

Leung H, Xiong L, Ni Y, Busch A, Bauer M, Press AT, Panagiotou G (2023) Impaired flux of bile acids from the liver to the gut reveals microbiome-immune interactions associated with liver damage. *NPJ Biofilms and microbiomes* 9(1), 35.

Mirhakkak MH^{*}, Chen X^{*}, Heinekamp T, Sae-Ong T, Xu LL, Ni Y, Kurzai O, Barber AE, Brakhage AA, Boutin S, Schäuble S[#], Panagiotou G[#] (2023) Genome-scale Metabolic modeling of *Aspergillus fumigatus* strains reveals growth dependencies on the lung microbiome. *Nat Commun* 14(1), 4369.

Ni Y^{*}, Qian L^{*}, Leal Siliceo S^{*}, Long X^{*}, Nychas E, Liu Y, Ismaiah MJ, Leung H, Zhang L, Gao Q, Wu Q, Zhang Y, Jia Xi, Liu S, Yuan R, Zhou L, Wang X, Li Q, Zhao Y, El-Nezami H, Xu A, Xu G[#], Li H[#], Panagiotou G[#], Jia W[#] (2023) Resistant starch decreases intrahepatic triglycerides in NAFLD patients via gut microbiome alterations. *Cell Metab* 35(9), 1530-1547.

Leung H, Long X, Ni Y, Qian L, Nychas E, Siliceo SL, Pohl D, Hanhineva K, Liu Y, Xu A, Nielsen HB, Belda E, Clément K, Loomba R, Li H, Jia W, Panagiotou G (2022) Risk assessment with gut microbiome and metabolite markers in NAFLD development. *Sci Transl Med* 14(648), eabk0855.

Kang K, Imamovic L, Misiakou M, Sørensen MB, Heshiki Y, Ni Y, Zheng T, Li J, Ellabaan MMH, Colomer-Lluch M, Rode AA, Bytzer P, Panagiotou G[#], Sommer MOA (corresponding author[#]) (2021) Expansion and persistence of antibiotic-specific resistance genes following antibiotic treatment. *Gut Microbes* 13(1), 1-19.

Marfil-Sánchez A^{*}, Seelbinder B^{*}, Ni Y, Varga J, Berta J, Hollosi V, Dome B, Megyesfalvi Z, Dulka E, Galffy G, Weiss GJ, Panagiotou G[#], Zoltan Lohinai Z[#] (2021) Gut microbiome functionality might be associated with exercise tolerance and recurrence of resected early-stage lung cancer patients. *PLOS One* 16(11), e0259898.

Marfil-Sánchez A^{*}, Zhang L^{*}, Alonso-Pernas P, Mirhakkak M, Mueller M, Seelbinder B, Ni Y, Santhanam R, Busch A, Beemelmanns C, Ermolaeva M, Bauer M[#], Panagiotou G[#] (2021) An integrative understanding of the large metabolic shifts induced by antibiotics in critical illness. *Gut Microbes* 13(1), 1993598.

Mirhakkak M, Schäuble S, Klassert T, Brunke S, Brandt P, Loos D, Uribe R, de Oliveira Lino FS, Ni Y, Vylkova S, Slevogt H, Hube B, Weiss G, Sommer M, Panagiotou G[#] (2021) Metabolic modeling predicts specific gut bacteria as key determinants for *Candida albicans* colonization levels. *ISME J* 15(5), 1257-1270.

Ni Y^{*}, Lohinai Z^{*}, Heshiki Y, Dome B, Moldvay J, Dulka E, Galffy G, Berta J, Weiss GJ, Sommer MOA, Panagiotou G[#] (2021) Distinct composition and metabolic functions of human gut microbiota

are associated with cachexia in lung cancer patients. *ISME J* 15(11), 3207-3220.

Zhang J, Ni Y, Qian L, Fang Q, Zheng T, Zhang M, Gao Q, Zhang Y, Ni J, Hou X, Bao Y, Kovatcheva-Datchary P, Xu A, Li H, Panagiotou G[#], Jia W (2021) Decreased abundance of *Akkermansia muciniphila* leads to the impairment of insulin secretion and glucose homeostasis in lean type 2 diabetes. *Adv Sci (Weinh)* 8(16), e2100536.

Heshiki Y, Vazquez-Uribe R, Li J, Ni Y, Quainoo S, Imamovic L, Li J, Sørensen M, Chow BKC, Weiss GJ, Xu A, Sommer MOA, Panagiotou G (2020) Predictable modulation of cancer treatment outcomes by the gut microbiota. *Microbiome* 8(1), 28.

Liu Y, Wang Y, Ni Y, Cheung CKY, Lam KSL, Wang Y, Xia Z, Ye D, Guo J, Tse MA, Panagiotou G^{**}, Xu A^{**} (corresponding authors^{**}) (2020) Gut microbiome fermentation determines the efficacy of exercise for diabetes prevention. *Cell Metab* 31(1), 77-91.

Nie X, Chen J, Ma X, Ni Y, Shen Y, Yu H, Panagiotou G^{**}, Bao Y^{**} (corresponding authors^{**}) (2020) A metagenome-wide association study of gut microbiome and visceral fat accumulation. *Comput Struct Biotechnol J* 18, 2596-2609.

Zhang L, Ouyang Y, Li H, Shen L, Ni Y, Fang Q, Wu G, Qian L, Xiao Y, Zhang J, Yin P, Panagiotou G, Xu G, Ye J, Jia W (2019) Metabolic phenotypes and the gut microbiota in response to dietary resistant starch type 2 in normal-weight subjects: a randomized crossover trial. *Sci Rep* 9(1), 4736.

Zheng T, Li J, Ni Y, Kang K, Misiakou MA, Imamovic L, Chow BKC, Rode AA, Bytzer P, Sommer M, Panagiotou G^{**} (2019) Mining, analyzing, and integrating viral signals from metagenomic data. *Microbiome* 7(1), 42.

Kang K, Ni Y, Li J, Imamovic L, Sarkar C, Kobler MD, Heshiki Y, Zheng T, Kumari S, Wong JCY, Archna A, Wong CWM, Dingle C, Denizen S, Baker DM, Sommer MOA, Webster CJ, Panagiotou G^{**} (2018) The environmental exposures and inner- and intercity traffic flows of the metro system may contribute to the human skin microbiome and resistome. *Cell Reports* 24(5), 1190-1202.

Heshiki Y, Dissanayake T, Zheng T, Kang K, Yueqiong N, Xu Z, Sarkar C, Woo PCY, Chow BKC, Baker D, Yan A, Webster CJ, Panagiotou G^{**}, Li J^{**} (2017) Toward a Metagenomic Understanding on the Bacterial Composition and Resistome in Hong Kong Banknotes. *Front Microbiol* 8, 632.

Ni Y, Jensen K, Kouskoumvekaki I^{**}, Panagiotou G^{**} (2017) NutriChem 2.0: exploring the effect of plant-based foods on human health and drug efficacy. *Database* (2017),

Zheng T, Ni Y, Li J, Chow BKC, Panagiotou G^{**} (2017) Designing Dietary Recommendations Using System Level Interactomics Analysis and Network-Based Inference. *Front Physiol* 8, 753.

*equal contribution [#]corresponding author